NSE filing, NSE: TORNTPHARM. Summary written from the filing by ALFA Finder's alert engine.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,738.50
- Market cap
- ₹1,80,237 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 84.9×Sector 41.3×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.22%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Revenue grew 51% following the JB Chemicals merger, but underlying business shows integration headwinds.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Debt & Borrowing
Torrent Pharmaceuticals filed its security cover certificate as on 30-Sep-26 for listed NCDs, showing 141% market-value cover. Secured debt covered by the certificate stands at Rs 11,578.42 Crore.
Torrent Pharmaceuticals Q2 FY27 Results: Net Profit ₹534 Cr, Down 9.6% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,979 Cr (+50.8% YoY) and net profit of ₹534 Cr (-9.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹534 Cr · -9.6% YoY
Torrent Pharmaceuticals Management Change
Torrent Pharmaceuticals' Executive Director, Amal Kelshikar, has resigned from his position effective October 16, 2026.
Torrent Pharmaceuticals Credit Rating
India Ratings affirmed Torrent Pharmaceuticals' existing credit ratings and revised the outlook to positive. The company's commercial paper rating was also affirmed and assigned.
Torrent Pharmaceuticals Board Meeting Date
Torrent Pharmaceuticals will hold a board meeting on 23-Oct-26 to consider standalone audited and consolidated unaudited financial results for the quarter and half-year ended 30-Sep-26.
Other other announcement announcements
All →Kansai Nerolac Paints Other Announcement
Kansai Nerolac authorised Pravin Chaudhari, Yash Ahuja and Rukmini Subramanian to determine material events from 1 December 2026. It only lists KMP and contact details.
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.
Physicswallah Other Announcement
Physicswallah's IPO monitoring report flags a deviation from offer objects for the quarter ended September 30, 2026. The diverted funds were restored on October 30, 2026.
Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
PDS Other Announcement
PDS Limited submitted the CRISIL Ratings monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation in the utilisation of its QIP proceeds.